

# CITATION REPORT

List of articles citing

Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology

DOI: 10.1016/s0161-6420(02)01168-5  
Ophthalmology, 2002, 109, 1377-82.

**Source:** <https://exaly.com/paper-pdf/34284437/citation-report.pdf>

**Version:** 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| #   | Paper   | IF  | Citations |
|-----|---|-----|-----------|
| 319 | Avaliaçã da toxicidade ocular por derivados da 4-aminoquinolona. <b>2002</b> , 65, 645-649  |     | 2         |
| 318 | Le d'istage de la toxicit' des antipalud'ens : notions courantes. <b>2002</b> , 37, 331-334   |     | 0         |
| 317 | Screening for antimalarial toxicity: current concepts. <b>2002</b> , 37, 325-8, 331-4   |     | 11        |
| 316 | Defining ideal body weight. <b>2002</b> , 134, 935; author reply 935-6  |     | 6         |
| 315 | Pharmacological treatment of established rheumatoid arthritis. <b>2003</b> , 17, 811-29   |     | 22        |
| 314 | Dosage of hydroxychloroquine should be based on ideal body weight: comment on the letter by Alarc' B. <b>2003</b> , 48, 863-4; author reply 864                   |     | 4         |
| 313 | Reply. <b>2003</b> , 48, 864-864  |     |           |
| 312 | Multicentric reticulohistiocytosis treated successfully with an anti-tumor necrosis factor agent: comment on the article by Gorman et al. <b>2003</b> , 48, 864-6 |     | 56        |
| 311 | Pharmacoepidemiology and drug safety. <b>2003</b> , 12, 73-88   |     |           |
| 310 | Mitochondrial membrane permeabilization is a critical step of lysosome-initiated apoptosis induced by hydroxychloroquine. <b>2003</b> , 22, 3927-36               |     | 315       |
| 309 | Ocular adverse drug reactions. <b>2003</b> , 2, 411-20  |     | 11        |
| 308 | The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. <i>Ophthalmology</i> , <b>2003</b> , 110, 1321-6       | 7.3 | 195       |
| 307 | Detecting chloroquine retinopathy: electro-oculogram versus colour vision. <b>2003</b> , 87, 902-8  |     | 34        |
| 306 | Multifocal electroretinography evaluation for early detection of retinal dysfunction in patients taking hydroxychloroquine. <b>2003</b> , 23, 503-12              |     | 47        |
| 305 | Coroidopatia l'pica: relato de 2 casos. <b>2004</b> , 67, 657-660   |     | 1         |
| 304 | The management of dermatomyositis: current treatment options. <b>2004</b> , 5, 1083-99  |     | 32        |
| 303 | Chloroquine gestational use in systemic lupus erythematosus: assessing the risk of child ototoxicity by pure tone audiometry. <b>2004</b> , 13, 223-7             |     | 31        |

|     |   |     |
|-----|---|-----|
| 302 | Adherence to guidelines for the monitoring of antimalarial-related retinal toxicity. <b>2004</b> , 43, 1058-9; author reply 1059  | 2   |
| 301 | The multifocal pattern electroretinogram in chloroquine retinopathy. <b>2004</b> , 36, 106-13   | 8   |
| 300 | Are evidence-based guidelines being followed for the monitoring of ocular toxicity of hydroxychloroquine? A nationwide survey of practice amongst consultant rheumatologists and implications for clinical governance. Comment on the article by Samanta et al. <b>2004</b> , 43, 1057-8; author reply 1059 | 4   |
| 299 | Skin manifestations of systemic autoimmune connective tissue disease: diagnostics and therapeutics. <b>2004</b> , 18, 429-62  | 35  |
| 298 | ERG findings in patients using hydroxychloroquine. <b>2004</b> , 108, 87-97   | 27  |
| 297 | [Analysis of 925 patients on long-term hydroxychloroquine or chloroquine treatment: results of ophthalmological screening]. <b>2004</b> , 27, 367-73  | 9   |
| 296 | Therapeutic strategies for rheumatoid arthritis. <b>2004</b> , 350, 2591-602  | 416 |
| 295 | [Up-dated ophthalmological screening and follow-up management for long-term antimalarial treatment]. <b>2004</b> , 27, 191-9  | 22  |
| 294 | The eye in systemic inflammatory diseases. <b>2004</b> , 364, 2125-33   | 57  |
| 293 | Drug-induced corneal complications. <b>2004</b> , 15, 541-8   | 84  |
| 292 | The utility of multifocal electroretinography in monitoring drug toxicity: deferoxamine retinopathy. <b>2004</b> , 39, 656-61   | 13  |
| 291 | Multifocal electroretinographic evaluation of long-term hydroxychloroquine users. <b>2004</b> , 122, 973-81   | 102 |
| 290 | Pediatric rheumatology for the adult rheumatologist I: therapy and dosing for pediatric rheumatic disorders. <b>2005</b> , 11, 21-33  | 5   |
| 289 | Ocular toxicity due to chloroquine and hydroxychloroquine: electrophysiological and visual function correlates. <b>2005</b> , 110, 111-20   | 48  |
| 288 | Subacute Cutaneous and Systemic Lupus Erythematosus. <b>2005</b> , 203-228  | 1   |
| 287 | Hydroxychloroquine screening. <b>2005</b> , 89, 521-2   | 12  |
| 286 | Vision restoration therapy. <b>2005</b> , 89, 522-4   | 29  |
| 285 | Threshold Amsler grid as a screening tool for asymptomatic patients on hydroxychloroquine therapy. <b>2005</b> , 89, 569-74   | 18  |

|     |   |     |
|-----|---|-----|
| 284 | Treatment of Rheumatoid Arthritis in the Elderly. <b>2005</b> , 35, 151-154   |     |
| 283 | [Ophthalmologic prevention of chloroquine and hydroxychloroquine induced retinopathy]. <b>2005</b> , 132, 329-37  | 1   |
| 282 | Multifocal electroretinographic changes in patients receiving hydroxychloroquine therapy. <b>2005</b> , 140, 794-807  | 86  |
| 281 | The dilemma of hydroxychloroquine screening: new information from the multifocal ERG. <b>2005</b> , 140, 894-5  | 29  |
| 280 | CHRONIC ARTHRITIS IN CHILDHOOD. <b>2005</b> , 206-260   | 50  |
| 279 | [Antimalarials: an update in rheumatic diseases]. <b>2006</b> , 2, 190-201  | 8   |
| 278 | Hydroxychloroquine-induced retinopathy: a dermatologic perspective. <b>2006</b> , 7, 171-5  | 7   |
| 277 | Management of cutaneous dermatomyositis: current therapeutic options. <b>2006</b> , 7, 341-51   | 36  |
| 276 | Lupus erythematosus: systemic and cutaneous manifestations. <b>2006</b> , 24, 348-62  | 112 |
| 275 | Ocular manifestations of systemic lupus erythematosus: a clinical review. <b>2006</b> , 15, 3-12  | 63  |
| 274 | Abnormalities on the multifocal electroretinogram may precede clinical signs of hydroxychloroquine retino-toxicity. <b>2006</b> , 20, 129-32                                | 15  |
| 273 | Visual field and multifocal electroretinography and their correlations in patients on hydroxychloroquine therapy. <b>2006</b> , 112, 177-87                                 | 44  |
| 272 | Retinal nerve fibre layer thickness measurements in patients using chloroquine. <b>2006</b> , 34, 130-6   | 22  |
| 271 | Hydroxychloroquine in lupus pregnancy. <b>2006</b> , 54, 3640-7   | 362 |
| 270 | Therapy insight: The recognition and treatment of retinal manifestations of systemic vasculitis. <b>2006</b> , 2, 443-51  | 10  |
| 269 | Early paracentral visual field loss in patients taking hydroxychloroquine. <b>2006</b> , 124, 1729-33   | 42  |
| 268 | Fundus autofluorescence and mfERG for early detection of retinal alterations in patients using chloroquine/hydroxychloroquine. <b>2006</b> , 47, 3531-8                     | 110 |
| 267 | Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). <b>2007</b> , 66, 1168-72 | 320 |

|     |   |     |
|-----|---|-----|
| 266 | [Diagnostics in childhood uveitis: what tests for which uveitis?]. <b>2007</b> , 224, 494-9   | 1   |
| 265 | Current and emerging strategies for the management of sarcoidosis. <b>2007</b> , 8, 1293-311  | 15  |
| 264 | Ocular manifestations of systemic lupus erythematosus. <b>2007</b> , 46, 1757-62  | 144 |
| 263 | EARLY PARACENTRAL VISUAL FIELD LOSS IN PATIENTS TAKING HYDROXYCHLOROQUINE. <b>2007</b> , 8, 94-95                                   |     |
| 262 | High-speed ultra-high-resolution optical coherence tomography findings in hydroxychloroquine retinopathy. <b>2007</b> , 125, 775-80 | 108 |
| 261 | Optical coherence tomography findings in hydroxychloroquine and chloroquine-associated maculopathy. <b>2007</b> , 1, 128-30         | 8   |
| 260 | Missing the bull's eye. <b>2007</b> , 52, 440-2   | 8   |
| 259 | Elderly-onset systemic lupus erythematosus: prevalence, clinical course and treatment. <b>2007</b> , 24, 701-15                     | 44  |
| 258 | Ocular adverse effects associated with systemic medications : recognition and management. <b>2007</b> , 67, 75-93                   | 115 |
| 257 | [Ocular toxicity due to 4-aminoquinoline derivatives]. <b>2007</b> , 70, 1046-51  | 8   |
| 256 | New concepts in antimalarial use and mode of action in dermatology. <b>2007</b> , 20, 160-74  | 185 |
| 255 | The biology behind the new therapies for SLE. <b>2007</b> , 61, 2113-9  | 19  |
| 254 | [Chloroquine/hydroxychloroquine: variability of retinotoxic cumulative doses]. <b>2007</b> , 104, 875-9                             | 27  |
| 253 | Chloroquine-induced bull's eye maculopathy in rheumatoid arthritis: related to disease duration?. <b>2007</b> , 26, 1248-53         | 25  |
| 252 | Retinal safety of a new fluoroquinolone, pradofloxacin, in cats: assessment with electroretinography. <b>2008</b> , 116, 177-91     | 38  |
| 251 | [Typical questions from the rheumatologist to the ophthalmologist and cooperating radiologist]. <b>2008</b> , 67, 360-4, 366-71     |     |
| 250 | Hydroxychloroquine-induced hyperpigmentation: the staining pattern. <b>2008</b> , 35, 1134-7  | 40  |
| 249 | Retinal toxicity secondary to Plaquenil therapy. <b>2008</b> , 79, 90-4   | 8   |

|     |   |     |
|-----|---|-----|
| 248 | Lupus Nephritis. <b>2008</b> , 157-171  | 1   |
| 247 | Treatment of sarcoidosis. <b>2008</b> , 29, 533-48, ix-x  | 121 |
| 246 | [Hydroxychloroquine and systemic lupus: a reappraisal]. <b>2008</b> , 29, 735-7   | 9   |
| 245 | Drug-induced ocular side effects. <b>2008</b> , 45-287  |     |
| 244 | Stratégies thérapeutiques actuelles dans les principaux rhumatismes inflammatoires chroniques. <b>2008</b> , 4, 26-34                     |     |
| 243 | Ocular toxicity of hydroxychloroquine. <b>2008</b> , 23, 201-9  | 74  |
| 242 | Hydroxychloroquine retinopathy screening. <b>2008</b> , 92, 1653-5  | 16  |
| 241 | A novel method for screening the multifocal electroretinogram in patients using hydroxychloroquine. <b>2008</b> , 28, 1478-86             | 26  |
| 240 | Clinical electrophysiology in quinine induced retinal toxicity. <b>2008</b> , 85, 17-26   | 8   |
| 239 | [Toxic maculopathy caused by antimalarial drugs: detection using spectral domain OCT: case reports]. <b>2009</b> , 72, 710-4              | 1   |
| 238 | Early detection of macular changes with multifocal ERG in patients on antimalarial drug therapy. <b>2009</b> , 25, 249-58                 | 16  |
| 237 | [Retinal damage by (hydroxy)chloroquine intake: published evidence for an efficient ophthalmological follow-up]. <b>2009</b> , 226, 891-6 | 3   |
| 236 | Therapeutic options for rheumatoid arthritis. <b>2009</b> , 10, 2095-106  | 24  |
| 235 | Visual neurophysiological dysfunction in infants exposed to hydroxychloroquine in utero. <b>2009</b> , 98, 1500-3                         | 19  |
| 234 | A quality indicator set for systemic lupus erythematosus. <b>2009</b> , 61, 370-7   | 107 |
| 233 | Detection of the regression on hydroxychloroquine retinopathy in optical coherence tomography. <b>2009</b> , 28, 607-9                    | 13  |
| 232 | [Skin and eyes]. <b>2009</b> , 60, 63-74; quiz 75   | 2   |
| 231 | Systemic lupus erythematosus in the elderly: antimalarials in disease remission. <b>2009</b> , 29, 1087-90                                | 6   |

|     |   |     |
|-----|---|-----|
| 230 | [Antimalarials. A treatment option for every lupus patient!?. <b>2009</b> , 68, 584, 586-90   | 4   |
| 229 | [Antimalarial $\beta$ retinopathy remains a current threat]. <b>2009</b> , 38, 662-3  |     |
| 228 | Retinal Angiography and Optical Coherence Tomography. <b>2009</b> ,   | 12  |
| 227 | Systemic Lupus Erythematosus. <b>2009</b> , 131-159   | 2   |
| 226 | Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis. <b>2009</b> , 26, 273-93  | 19  |
| 225 | Cutaneous lupus erythematosus: issues in diagnosis and treatment. <b>2009</b> , 10, 365-81  | 176 |
| 224 | Preferential Hyperacuity Perimetry to detect hydroxychloroquine retinal toxicity. <b>2009</b> , 29, 1188-92   | 8   |
| 223 | [Skin and eyes]. <b>2010</b> , 107, 281-92; quiz 293  | 1   |
| 222 | Macular sensitivity changes for detection of chloroquine toxicity in asymptomatic patient. <b>2010</b> , 30, 195-7  | 8   |
| 221 | Normalization of generalized retinal function and progression of maculopathy after cessation of therapy in a case of severe hydroxychloroquine retinopathy with 19 years follow-up. <b>2010</b> , 120, 251-64 | 15  |
| 220 | Why all systemic lupus erythematosus patients should be given hydroxychloroquine treatment?. <b>2010</b> , 77, 4-5  | 26  |
| 219 | Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. <b>2010</b> , 62, 775-84  | 184 |
| 218 | Pourquoi faut-il traiter tous les patients atteints de lupus systématique par hydroxychloroquine ?. <b>2010</b> , 77, 4-6   |     |
| 217 | Effects of chronic exposure to hydroxychloroquine or chloroquine on inner retinal structures. <b>2010</b> , 24, 340-6   | 55  |
| 216 | Selective thinning of the perifoveal inner retina as an early sign of hydroxychloroquine retinal toxicity. <b>2010</b> , 24, 756-62; quiz 763   | 45  |
| 215 | Hydroxychloroquine retinopathy: screening needed to prevent blindness. <b>2010</b> , 192, 668-9   | 3   |
| 214 | Spectral domain optical coherence tomography as an effective screening test for hydroxychloroquine retinopathy (the "flying saucer" sign). <b>2010</b> , 4, 1151-8  | 83  |
| 213 | Retinal toxicity of systemic and topical medications. <b>2010</b> , 104-121   | 2   |

|     |   |        |
|-----|---|--------|
| 212 | [Ocular complications of chloroquine and derivatives therapy]. <b>2010</b> , 73, 384-9  | 11     |
| 211 | [Optical coherence tomography to evaluate peripapillary retinal nerve fiber layer in chloroquine patients]. <b>2010</b> , 73, 28-32   | 3      |
| 210 | Medical Treatment of Rheumatoid Arthritis: A Review. <b>2010</b> , 28, 30-39  |        |
| 209 | Fundus autofluorescence and spectral domain optical coherence tomography in early detection of Plaquenil maculopathy. <b>2010</b> , 20, 785-8   | 13     |
| 208 | Ocular side effects of anti-rheumatic medications: what a rheumatologist should know. <b>2010</b> , 19, 675-82  | 32     |
| 207 | Treatment of cutaneous lupus erythematosus. <b>2010</b> , 19, 1125-36   | 33     |
| 206 | European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. <b>2010</b> , 69, 1269-74 | 245    |
| 205 | Management of the Connective Tissue Diseases of Childhood. <b>2010</b> , 249-274  |        |
| 204 | A new role for antimalarials in systemic lupus erythematosus treatment. <b>2010</b> , 5, 299-312  | 1      |
| 203 | Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. <b>2010</b> , 69, 20-8  | 645    |
| 202 | Hydroxychloroquine and lichen planopilaris: efficacy and introduction of Lichen Planopilaris Activity Index scoring system. <b>2010</b> , 62, 387-92                                      | 121    |
| 201 | Retinopathy due to antimalarial drugs in patients with connective tissue diseases: are they so innocent? A single center retrospective study. <b>2010</b> , 13, e11-5                     | 17     |
| 200 | Tratamiento antiparasitario. <b>2010</b> , 10, 3664-3672  |        |
| 199 | Evaluation of risk factors for retinal damage due to chloroquine and hydroxychloroquine. <b>2010</b> , 94, 1637-42  | 27     |
| 198 | Systemic lupus erythematosus: safe and effective management in primary care. <b>2010</b> , 37, 767-78, vii  | 3      |
| 197 | The role of antimalarial agents in the treatment of SLE and lupus nephritis. <b>2011</b> , 7, 718-29  | 166    |
| 196 | Cutaneous lupus erythematosus: update of therapeutic options part I. <b>2011</b> , 65, e179-93  | 120    |
| 195 | Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. <i>Ophthalmology</i> , <b>2011</b> , 118, 415-22   | 73 449 |



|     |  |     |     |
|-----|--|-----|-----|
| 194 | Author reply. <i>Ophthalmology</i> , <b>2011</b> , 118, 2098-2099  | 7.3 |     |
| 193 | Amsler grids for chloroquine toxicity. <i>Ophthalmology</i> , <b>2011</b> , 118, 2099; author reply 2099-100   | 7.3 | 1   |
| 192 | Author reply. <i>Ophthalmology</i> , <b>2011</b> , 118, 2099-2100  | 7.3 | 3   |
| 191 | Hydroxychloroquine retinopathy: screening needed to prevent blindness. <b>2011</b> , 194, 55   |     |     |
| 190 | Antimalarials and SLE. <b>2011</b> , 1061-1081   |     | 0   |
| 189 | Update on the use of topical calcineurin inhibitors in cutaneous lupus erythematosus. <b>2011</b> , 5, 21-31   |     | 14  |
| 188 | Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action. <b>2011</b> , 23, 278-81  |     | 73  |
| 187 | Ocular Complications of Drugs Used in Rheumatic Disease. <b>2011</b> , 7, 61-68  |     |     |
| 186 | Ocular complications of systemic medications. <b>2011</b> , 342, 62-9  |     | 24  |
| 185 | Retina in rheumatic diseases: standard full field and multifocal electroretinography in hydroxychloroquine retinal dysfunction. <i>Australasian journal of optometry, The</i> , <b>2011</b> , 94, 276-83   | 2.7 | 14  |
| 184 | Retinal disorders in northern Brazilian patients treated with chloroquine assessed by multifocal ERG. <b>2011</b> , 122, 77-86   |     | 3   |
| 183 | A comparative study of the usefulness of color vision, photostress recovery time, and visual evoked potential tests in early detection of ocular toxicity from hydroxychloroquine. <b>2011</b> , 31, 283-9 |     | 12  |
| 182 | Retinal functional changes measured by frequency-doubling technology in patients treated with hydroxychloroquine. <b>2011</b> , 249, 715-21  |     | 10  |
| 181 | Treatment of cutaneous lupus. <b>2011</b> , 13, 300-7  |     | 46  |
| 180 | Clinical characteristics of hydroxychloroquine retinopathy. <b>2011</b> , 95, 245-50   |     | 18  |
| 179 | Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy. <b>2011</b> , 129, 30-9  |     | 141 |
| 178 | Retinal disorders. <b>2011</b> , 102, 97-116   |     | 5   |
| 177 | Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature. <b>2011</b> , 38, 2504-8   |     | 50  |

|     |   |     |
|-----|---|-----|
| 176 | Use of hydroxychloroquine in Japan. <b>2012</b> , 39, 1296  | 7   |
| 175 | Cardiomyopathy caused by longterm treatment with chloroquine: a rare disease, or a rare diagnosis?. <b>2012</b> , 39, 1099-103  | 20  |
| 174 | Retinal and cochlear toxicity of drugs: new insights into mechanisms and detection. <b>2012</b> , 25, 76-85   | 4   |
| 173 | A novel role for Hucopherol transfer protein (HHTP) in protecting against chloroquine toxicity. <b>2012</b> , 287, 2926-34  | 14  |
| 172 | Tratamiento del lupus eritematoso cutáneo resistente. <b>2012</b> , 13, 77-84   |     |
| 171 | Clinically evident chloroquine toxicity undetected by multifocal electroretinogram. <b>2012</b> , 47, e31-3   | 2   |
| 170 | Low-dose hydroxychloroquine is as effective as phlebotomy in treatment of patients with porphyria cutanea tarda. <b>2012</b> , 10, 1402-9   | 59  |
| 169 | Diagnosis and treatment of urticaria and angioedema: a worldwide perspective. <b>2012</b> , 5, 125-47   | 118 |
| 168 | Ocular toxicity from systemically administered xenobiotics. <b>2012</b> , 8, 1277-91  | 27  |
| 167 | [Critical review of the new recommendations on screening for hydroxychloroquine retinopathy]. <b>2012</b> , 33, 265-7   | 4   |
| 166 | Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects. <b>2012</b> , 42, 968-78   | 73  |
| 165 | Successful treatment of a novel generalized variant of canine discoid lupus erythematosus with oral hydroxychloroquine. <b>2012</b> , 23, 65-70, e15-6  | 27  |
| 164 | Comparison of different screening methods for chloroquine/hydroxychloroquine retinopathy: multifocal electroretinography, color vision, perimetry, ophthalmoscopy, and fluorescein angiography. <b>2012</b> , 250, 319-25 | 23  |
| 163 | Ocular, Aural, and Oral Manifestations. <b>2013</b> , 393-400   | 2   |
| 162 | Chloroquine: modes of action of an undervalued drug. <b>2013</b> , 153, 50-7  | 92  |
| 161 | [Ophthalmologic screening history and vision-targeted health status of patients suffering from chloroquine maculopathy]. <b>2013</b> , 110, 654-62  | 2   |
| 160 | Chloroquine cardiomyopathy - a review of the literature. <b>2013</b> , 35, 434-42   | 120 |
| 159 | BukaB Emergencies in Dermatology. <b>2013</b> ,   |     |

|     |  |     |
|-----|--|-----|
| 158 | Cutaneous lupus erythematosus: diagnosis and treatment. <b>2013</b> , 27, 391-404  | 152 |
| 157 | Impact of the revised american academy of ophthalmology guidelines regarding hydroxychloroquine screening on actual practice. <b>2013</b> , 155, 418-428.e1  | 53  |
| 156 | Refractory immune thrombocytopenia successfully treated with high-dose vitamin D supplementation and hydroxychloroquine: two case reports. <b>2013</b> , 7, 91   | 18  |
| 155 | Microperimetric sensitivity in patients on hydroxychloroquine (Plaquenil) therapy. <b>2013</b> , 27, 1044-52   | 16  |
| 154 | Chloroquine and hydroxychloroquine retinopathy-related risk factors in a Turkish cohort. <b>2013</b> , 33, 627-34  | 9   |
| 153 | Retinitis Pigmentosa and Allied Disorders. <b>2013</b> , 761-835   | 4   |
| 152 | Chinese Herbal Medicine (Zi Shen Qing) for Mild-to-Moderate Systemic Lupus Erythematosus: A Pilot Prospective, Single-Blinded, Randomized Controlled Study. <b>2013</b> , 2013, 327245   | 10  |
| 151 | Prevalence and risk factors for chloroquine maculopathy and role of plasma chloroquine and desethylchloroquine concentrations in predicting chloroquine maculopathy. <b>2013</b> , 16, 47-55                                       | 6   |
| 150 | Hard palate hyperpigmentation secondary to chronic chloroquine therapy: report of five cases. <b>2013</b> , 40, 833-8  | 18  |
| 149 | A cross-sectional study of hydroxychloroquine concentrations and effects in people with systemic lupus erythematosus. <b>2013</b> , 43, 547-53   | 15  |
| 148 | Relative sensitivity and specificity of 10-2 visual fields, multifocal electroretinography, and spectral domain optical coherence tomography in detecting hydroxychloroquine and chloroquine retinopathy. <b>2014</b> , 8, 1389-99 | 38  |
| 147 | Ocular Manifestations of Systemic Lupus Erythematosus. <b>2014</b> , 05,   | 0   |
| 146 | The impact of different algorithms for ideal body weight on screening for hydroxychloroquine retinopathy in women. <b>2014</b> , 8, 1401-7   | 11  |
| 145 | Retinal damage in chloroquine maculopathy, revealed by high resolution imaging: a case report utilizing adaptive optics scanning laser ophthalmoscopy. <b>2014</b> , 28, 100-7   | 10  |
| 144 | Visual fields in a chloroquine treatment. <b>2014</b> , 59   |     |
| 143 | Hydroxychloroquine-induced cardiomyopathy: case report, pathophysiology, diagnosis, and treatment. <b>2014</b> , 30, 1706-15   | 92  |
| 142 | Hydroxychloroquine and Chloroquine Retinopathy. <b>2014</b> ,  | 25  |
| 141 | Microperimetry and Multimodal Retinal Imaging. <b>2014</b> ,   | 4   |

|     |  |     |
|-----|--|-----|
| 140 | Regular examinations for toxic maculopathy in long-term chloroquine or hydroxychloroquine users. <b>2014</b> , 132, 1199-208   | 38  |
| 139 | Retinotoxicity of Hydroxychloroquine: Is It Possible to Demonstrate by Spectral Domain Optical Coherence Tomography Before Development? A Cross Sectional Investigation. <b>2014</b> , 29, 178-185 | 2   |
| 138 | Antipalúdicos en dermatologí: mecanismo de acci3n, indicaciones y efectos secundarios. <b>2014</b> , 105, 243-252  | 27  |
| 137 | The diagnosis and management of acute and chronic urticaria: 2014 update. <b>2014</b> , 133, 1270-7  | 389 |
| 136 | Ten common mistakes in the management of lupus nephritis. <b>2014</b> , 63, 667-76   | 28  |
| 135 | Cutaneous porphyrias part II: treatment strategies. <b>2014</b> , 53, 3-24   | 16  |
| 134 | Pharmacokinetics, electrophysiological, and morphological effects of the intravitreal injection of mycophenolic acid in rabbits. <b>2014</b> , 30, 502-11  | 5   |
| 133 | Antimalarials in dermatology: mechanism of action, indications, and side effects. <b>2014</b> , 105, 243-52  | 14  |
| 132 | Chloroquine cardiomyopathy: beyond ocular adverse effects. <b>2014</b> , 2014,   | 9   |
| 131 | Active surveillance of visual impairment due to adverse drug reactions: findings from a national study in the United Kingdom. <b>2015</b> , 3, e00107  | 1   |
| 130 | Chapter 8: Toxic Maculopathy/Retinopathy. <b>2015</b> , 61-70  |     |
| 129 | Advanced hydroxychloroquine maculopathy against medical advice. <b>2015</b> , 2,   |     |
| 128 | Decreased Perifoveal Sensitivity Detected by Microperimetry in Patients Using Hydroxychloroquine and without Visual Field and Fundoscopic Anomalies. <b>2015</b> , 2015, 437271                    | 12  |
| 127 | Hydroxychloroquine Retinopathy. <b>2015</b> , 22, 140  |     |
| 126 | Detection of Hydroxychloroquine Retinal Toxicity by Automated Perimetry in 60 Rheumatoid Arthritis Patients with Normal Fundoscopic Findings. <b>2015</b> , 8, 59-64                               | 4   |
| 125 | Spectral-Domain Optical Coherence Tomography of Preclinical Chloroquine Maculopathy in Egyptian Rheumatoid Arthritis Patients. <b>2015</b> , 2015, 292357  | 6   |
| 124 | The Diagnosis and Treatment of Systemic Lupus Erythematosus. <b>2015</b> , 112, 423-32   | 81  |
| 123 | Retinal toxicity of high-dose hydroxychloroquine in patients with chronic graft-versus-host disease. <b>2015</b> , 50, 442-50  | 19  |

|     |  |    |     |
|-----|--|----|-----|
| 122 | Hydroxychloroquine and chloroquine retinopathy: a systematic review evaluating the multifocal electroretinogram as a screening test. <i>Ophthalmology</i> , <b>2015</b> , 122, 1239-1251.e4                          | 73 | 31  |
| 121 | Evaluation of Crimean-Congo hemorrhagic fever virus in vitro inhibition by chloroquine and chlorpromazine, two FDA approved molecules. <b>2015</b> , 118, 75-81  |    | 31  |
| 120 | [Clinical evaluation of the new screening procedures for hydroxychloroquine retinopathy, according to the American Academy of Ophthalmology guidelines. Prospective study of 184 patients]. <b>2015</b> , 38, 377-87 |    | 1   |
| 119 | Hydroxychloroquine screening practice patterns within a large multispecialty ophthalmic practice. <b>2015</b> , 160, 561-568.e2  |    | 12  |
| 118 | Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. <b>2015</b> , 23, 231-69                       |    | 300 |
| 117 | Subjective and objective screening tests for hydroxychloroquine toxicity. <i>Ophthalmology</i> , <b>2015</b> , 122, 356-66   | 73 | 44  |
| 116 | Value of Antimalarial Drugs in the Treatment of Lupus. <b>2016</b> , 515-520   |    |     |
| 115 | Effect of Hydroxychloroquine on the Retinal Layers: A Quantitative Evaluation with Spectral-Domain Optical Coherence Tomography. <b>2016</b> , 2016, 8643174   |    | 15  |
| 114 | Current and emerging treatment options in the management of lupus. <b>2016</b> , 5, 9-20   |    | 28  |
| 113 | AIMING FOR THE BULL'S EYE: The Cost-Utility of Screening for Hydroxychloroquine Retinopathy. <b>2016</b> , 36, 1958-63   |    | 1   |
| 112 | Ocular changes induced by drugs commonly used in dermatology. <b>2016</b> , 34, 129-37   |    | 9   |
| 111 | Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). <i>Ophthalmology</i> , <b>2016</b> , 123, 1386-94   | 73 | 596 |
| 110 | The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study. <b>2016</b> , 74, 693-9.e3                     |    | 44  |
| 109 | Hydroxychloroquine-related retinal toxicity. <b>2016</b> , 55, 957-67  |    | 57  |
| 108 | Hydroxychloroquine retinopathy. <b>2017</b> , 31, 828-845  |    | 99  |
| 107 | Cancer cachexia associates with a systemic autophagy-inducing activity mimicked by cancer cell-derived IL-6 trans-signaling. <b>2017</b> , 7, 2046   |    | 62  |
| 106 | Screening for hydroxychloroquine retinal toxicity: Current recommendations. <b>2017</b> , 14, 27-30  |    |     |
| 105 | Nonbiologic Drugs in Pediatric Rheumatology. <b>2017</b> , 55-75   |    |     |

|     |  |    |
|-----|--|----|
| 104 | Optical Coherence Tomography Protocols for Screening of Hydroxychloroquine Retinopathy in Asian Patients. <b>2017</b> , 184, 11-18   | 17 |
| 103 | Choroidal Thinning Associated With Hydroxychloroquine Retinopathy. <b>2017</b> , 183, 56-64  | 24 |
| 102 | Recomendações da Sociedade Brasileira de Reumatologia para diagnóstico e tratamento da febre chikungunya. Parte 2 - Tratamento. <b>2017</b> , 57, 438-451  | 20 |
| 101 | Recommendations of the Brazilian Society of Rheumatology for the diagnosis and treatment of chikungunya fever. Part 2 - Treatment. <b>2017</b> , 57 Suppl 2, 438-451   | 9  |
| 100 | PANRETINAL DEGENERATION ASSOCIATED WITH LONG-TERM HYDROXYCHLOROQUINE USE AND HETEROZYGOUS USH2A MUTATION. <b>2017</b> , 11 Suppl 1, S77-S80  | 4  |
| 99  | S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). <b>2017</b> , 31, 389-404    | 75 |
| 98  | Traditional DMARDs: Methotrexate, Leflunomide, Sulfasalazine, Hydroxychloroquine, and Combination Therapies. <b>2017</b> , 958-982.e7  | 2  |
| 97  | Hydroxychloroquine for treatment of rheumatoid arthritis: multifocal electroretinogram and laser flare-cell photometry study. <b>2017</b> , 11, 689-696  | 8  |
| 96  | Frequency and Clinical Characteristics of Hydroxychloroquine Retinopathy in Korean Patients with Rheumatologic Diseases. <b>2017</b> , 32, 522-527   | 13 |
| 95  | Baseline Retinal Examinations in Patients With Systemic Lupus Erythematosus Newly Initiating Hydroxychloroquine Treatment in a US Medicaid Systemic Lupus Erythematosus Population, 2000-2010. <b>2018</b> , 70, 1700-1706 | 4  |
| 94  | Multimodal Imaging in Drug-Related Retinal Toxicity. <b>2018</b> , 29-50   |    |
| 93  | Macular ganglion cell-inner plexiform layer thickness for detection of early retinal toxicity of hydroxychloroquine. <b>2018</b> , 38, 1635-1640   | 12 |
| 92  | Changing antimalarial agents after inefficacy or intolerance in patients with cutaneous lupus erythematosus: A multicenter observational study. <b>2018</b> , 78, 107-114.e1   | 24 |
| 91  | Hydroxychloroquine retinopathy - implications of research advances for rheumatology care. <b>2018</b> , 14, 693-703  | 99 |
| 90  | Early morpho-functional changes in patients treated with hydroxychloroquine: a prospective cohort study. <b>2018</b> , 256, 2201-2210  | 6  |
| 89  | Optical Coherence Tomography Minimum Intensity as an Objective Measure for the Detection of Hydroxychloroquine Toxicity. <b>2018</b> , 59, 1953-1963   | 12 |
| 88  | Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines. <b>2018</b> , 20, 133   | 26 |
| 87  | Imaging of Hydroxychloroquine Toxicity with Fluorescence Lifetime Imaging Ophthalmoscopy. <b>2019</b> , 3, 814-825   | 9  |

|    |   |     |
|----|---|-----|
| 86 | Are the Current Recommendations for Chloroquine and Hydroxychloroquine Screening Appropriate?. <b>2019</b> , 45, 359-367  | 6   |
| 85 | The 2016 American Academy of Ophthalmology Hydroxychloroquine Dosing Guidelines For Short, Obese Patients. <b>2019</b> , 3, 809-813   | 4   |
| 84 | Fluorescence Lifetimes in Patients With Hydroxychloroquine Retinopathy. <b>2019</b> , 60, 2165-2172   | 8   |
| 83 | The Diagnostic Utility of Multifocal Electroretinography in Detecting Chloroquine and Hydroxychloroquine Retinal Toxicity. <b>2019</b> , 206, 132-139   | 14  |
| 82 | Screening for Hydroxychloroquine Retinopathy-Can We Do Better?. <b>2019</b> , 39, 423-425   | 2   |
| 81 | Ocular, Aural, and Oral Manifestations of Lupus. <b>2019</b> , 556-565  | 1   |
| 80 | TOXIC EFFECTS OF HYDROXYCHLOROQUINE ON THE CHOROID: Evidence From Multimodal Imaging. <b>2019</b> , 39, 1016-1026   | 14  |
| 79 | Retinal Complications in Patients with Systemic Lupus Erythematosus Treated with Antimalarial Drugs. <b>2020</b> , 47, 553-556  | 6   |
| 78 | Hydroxychloroquine Retinopathy in the Era of Advanced Imaging Modalities. <b>2020</b> , 60, 73-83   | 0   |
| 77 | Multifocal electroretinography in amblyopia. <b>2020</b> , 258, 683-691   | 6   |
| 76 | Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19. <b>2020</b> , 216, 107672  | 31  |
| 75 | Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial. <b>2020</b> , 56, 106143  | 51  |
| 74 | A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials. <b>2020</b> , 254, 117775   | 24  |
| 73 | Spectral domain optical coherence tomography-based prevalence of hydroxychloroquine maculopathy in Indian patients on hydroxychloroquine therapy: A utopia of underdiagnosis. <b>2020</b> , 76, 395-401 | 1   |
| 72 | Outer Nuclear Layer Damage for Detection of Early Retinal Toxicity of Hydroxychloroquine. <b>2020</b> , 8,  | 4   |
| 71 | Rethinking the Hydroxychloroquine Dosing and Retinopathy Screening Guidelines. <b>2020</b> , 219, 101-106   | 7   |
| 70 | Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis. <b>2020</b> , 9,   | 100 |
| 69 | Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review. <b>2020</b> , 23, 177-181        | 28  |

|    |  |    |
|----|--|----|
| 68 | Value of antimalarial drugs in the treatment of lupus. <b>2021</b> , 591-595   | 1  |
| 67 | COVID-19; current situation and recommended interventions. <b>2021</b> , 75, e13886  | 11 |
| 66 | Improving eye screening practice among pediatric rheumatology patients receiving hydroxychloroquine. <b>2021</b> , 30, 269-279                           | 1  |
| 65 | Anti-Infectives. <b>2021</b> , 19-85   |    |
| 64 | The efficacy of antimalarial drugs in the therapy of selected forms of cicatricial alopecia. <b>2021</b> , 38, 302-309                                   | 0  |
| 63 | COVID-19: pathogenesis, advances in treatment and vaccine development and environmental impact-an updated review. <b>2021</b> , 28, 22241-22264          | 15 |
| 62 | Antimalarial-induced retinal toxicity. <b>2021</b> , 28, 132-132   | 0  |
| 61 | The Skin and the Eyes. 1-37  | 2  |
| 60 | Toxicology of Hydroxychloroquine and Chloroquine and the Pathology of the Retinopathy They Cause. <b>2014</b> , 65-83                                    | 3  |
| 59 | Retinitis Pigmentosa and Allied Disorders. <b>2006</b> , 395-498   | 12 |
| 58 | Vision loss. <b>2010</b> , 55-101  | 1  |
| 57 | Traditional DMARDs: Methotrexate, Leflunomide, Sulfasalazine, Hydroxychloroquine, and Combination Therapies. <b>2013</b> , 917-940.e6                    | 2  |
| 56 | Treatment of Systemic Lupus Erythematosus. <b>2013</b> , 1304-1330.e6  | 1  |
| 55 | Chloroquine and Hydroxychloroquine Toxicity. 2, 8  | 3  |
| 54 | Spectral-domain optical coherence tomography as a screening technique for chloroquine and hydroxychloroquine retinal toxicity. <b>2011</b> , 42, 493-7   | 8  |
| 53 | Multimodal imaging in a severe case of hydroxychloroquine toxicity. <b>2015</b> , 46, 377-9  | 16 |
| 52 | Hydroxychloroquine: A Brief Review on Screening, Toxicity, and Progression. <b>2016</b> , 47, 207-17   | 3  |
| 51 | Screening for chloroquine maculopathy in populations with uncertain reliability in outcomes of automatic visual field testing. <b>2016</b> , 64, 710-714 | 2  |



|    |   |    |
|----|---|----|
| 50 | Optical coherence tomography in a patient with chloroquine-induced maculopathy. <b>2008</b> , 56, 511-3   | 23 |
| 49 | Ocular Side Effects of Systemic Drugs Used in Dermatology. <b>2019</b> , 64, 423-430  | 1  |
| 48 | Evaluation of Maculopathy in Patients Using Hydroxychloroquine. <b>2019</b> , 49, 149-153   | 3  |
| 47 | One step derivatization and dispersive liquid-liquid microextraction of hydroxychloroquine sulfate for its sensitive and accurate determination using GC-MS. <b>2021</b> , 107130 | 1  |
| 46 | Topographic Variation of Retinal Vascular Density in Normal Eyes Using Optical Coherence Tomography Angiography. <b>2021</b> , 10, 15   | 2  |
| 45 | Drug Toxicity of the Posterior Segment. <b>2006</b> , 1839-1856   | 1  |
| 44 | Retinal Toxicity of Systemic Medications. <b>2008</b> , 2213-2224   |    |
| 43 | Neural (Sensory) Retina. <b>2009</b> , 393-480  |    |
| 42 | Methotrexate, Leflunomide, Sulfasalazine, Hydroxychloroquine, and Combination Therapies. <b>2009</b> , 883-907  | o  |
| 41 | Other Traditional Disease-Modifying Antirheumatic Drugs: Monotherapy and Combination Therapy. <b>2009</b> , 325-336   |    |
| 40 | Retinal Toxicity of Systemically Administered Drugs. <b>2009</b> , 761-765  |    |
| 39 | Systemic Therapy. 1-53  | 5  |
| 38 | Treatment of non-renal lupus. <b>2011</b> , 1307-1316.e4  |    |
| 37 | Subacute Cutaneous and Systemic Lupus Erythematosus. <b>2011</b> , 215-241  |    |
| 36 | Corneal Disease Associated with Nonrheumatoid Collagen-Vascular Disease. <b>2011</b> , 1133-1142  |    |
| 35 | Recommendations on How to Monitor the Patient with Systemic Lupus Erythematosus in the Clinic or at the Bedside. <b>2012</b> , 41-52  |    |
| 34 | Entzündliche Gefäßkrankungen. <b>2012</b> , 335-398   |    |
| 33 | Retinal and Choroidal Manifestations of Systemic Medications. <b>2013</b> , 479-492   | 6  |

|    |  |     |    |
|----|--|-----|----|
| 32 | Cutaneous Findings of Collagen Vascular Disease and Related Emergent Complications. <b>2013</b> , 207-234  |     |    |
| 31 | Toxic Retinopathies. <b>2014</b> , 163-170   |     |    |
| 30 | Ancillary Testing in Screening for Hydroxychloroquine and Chloroquine Retinopathy. <b>2014</b> , 155-226   |     |    |
| 29 | Screening for Hydroxychloroquine and Chloroquine Retinopathy. <b>2014</b> , 227-245  |     |    |
| 28 | Risk Factors for Hydroxychloroquine and Chloroquine Retinopathy. <b>2014</b> , 133-154   |     |    |
| 27 | Epidemiology of Hydroxychloroquine and Chloroquine Retinopathy. <b>2014</b> , 95-106   |     |    |
| 26 | Natural History of Hydroxychloroquine and Chloroquine Retinopathy. <b>2014</b> , 107-131   |     |    |
| 25 | Fundus auto fluorescence and spectral domain ocular coherence tomography in the early detection of chloroquine retinopathy. <b>2015</b> , 74,                            |     |    |
| 24 | Drug Induced Maculopathies. <b>2020</b> , 1-23   |     |    |
| 23 | Angiography in Pharmacologic Retinal Toxicity. <b>2009</b> , 199-213   |     |    |
| 22 | Ophthalmopbblem. Chloroquine or hydroxychloroquine retinopathy. <b>2005</b> , 51, 671, 679-80  |     |    |
| 21 | Improving the risk-benefit relationship and informed consent for patients treated with hydroxychloroquine. <b>2007</b> , 105, 191-4; discussion 195-7                    |     | 11 |
| 20 | Spectral-domain optical coherence tomography and adaptive optics may detect hydroxychloroquine retinal toxicity before symptomatic vision loss. <b>2009</b> , 107, 28-33 |     | 47 |
| 19 | Systemic lupus erythematosus. <i>Clinical Evidence</i> , <b>2009</b> , 2009,   |     | 0  |
| 18 | Highly Accelerated Onset of Hydroxychloroquine Macular Retinopathy. <i>Ochsner Journal</i> , <b>2017</b> , 17, 280-283   |     | 5  |
| 17 | Teleophthalmology Support for Primary Care Diagnosis and Management. <i>Medical Hypothesis, Discovery, and Innovation in Ophthalmology</i> , <b>2018</b> , 7, 57-62      | 1.4 | 6  |
| 16 | Ophthalmic manifestations of rheumatologic disease: diagnosis and management. <i>Missouri Medicine</i> , <b>2012</b> , 109, 53-8   | 0.8 | 3  |
| 15 | Hydroxychloroquine in Dermatology and Beyond: Recent Update. <i>Indian Dermatology Online Journal</i> , <b>2020</b> , 11, 453-464  | 0.9 | 5  |

|    |  |     |    |
|----|--|-----|----|
| 14 | Hydroxychloroquine in dermatology and beyond: Recent update. <i>Indian Dermatology Online Journal</i> , <b>2020</b> , 11, 453  | 0.9 | 10 |
| 13 | Retinal Disorders Mimicking Inherited Retinal Diseases. <b>2022</b> , 229-237  |     |    |
| 12 | Drug-induced corneal deposits: an up-to-date review.. <i>BMJ Open Ophthalmology</i> , <b>2022</b> , 7, e000943   | 3.2 | 0  |
| 11 | Targeting DAMPs with Nucleic Acid Scavengers to Treat Lupus.. <i>Translational Research</i> , <b>2022</b> ,  | 11  | 1  |
| 10 | Using of Hydroxychloroquine in Patients with Immunoglobulin A-nephropathy and Isolated Urine Syndrome. <b>2020</b> , 483-492   |     |    |
| 9  | Drug Induced Maculopathies. <b>2022</b> , 3739-3761  |     |    |
| 8  | Effect of hydroxychloroquine or chloroquine and short wavelength light on retinal function and structure in mouse eyes.. <i>Australasian journal of optometry, The</i> , <b>2022</b> , 1-9 | 2.7 |    |
| 7  | Antimalarial agents. <b>2013</b> , 241-251.e3  |     | 3  |
| 6  | Unusual Presentation of Acute Hydroxychloroquine Retinopathy. <i>Ocular Immunology and Inflammation</i> , 1-4  | 2.8 | 0  |
| 5  | Ocular side effects of drugs administered systemically for treatment of nonocular diseases. <b>2022</b> , 491-507  |     |    |
| 4  | Drug Induced Maculopathies. <b>2022</b> , 1-23   |     | 0  |
| 3  | A nationwide survey of hydroxychloroquine retinopathy presenting to the hospital eye service in the United Kingdom.  |     | 0  |
| 2  | Hydroxychloroquine Dose and Risk for Incident Retinopathy.   |     | 0  |
| 1  | Efficacy of hydroxychloroquine in pre-exposure severe acute respiratory syndrome coronavirus 2 prophylaxis among high-risk healthcare workers: A multicenter study. <b>2023</b> , 12, 3    |     | 0  |